Prøve GULL - Gratis
Gold, silver may turn volatile after two years of stellar rally
Mint Chennai
|December 29, 2025
Lower central bank purchases, stronger dollar, cooling safe-haven demand could cap gains
After a two-year run of stellar gains, US traders are signalling far more modest returns for gold and silver in 2026, possibly driven by lower central bank purchases, a stronger dollar, and moderating safe-haven demand, according to experts.
Analysts and financial planners are warning domestic investors to brace for bouts of volatility next year, with corrections in silver likely to be sharper, even though expectations could shift with changes in global macro conditions—such as interest rate moves or rising economic uncertainty.
Trader bets on Comex, the world’s most diverse derivatives marketplace, show they expect the most liquid gold futures contract to rise 3.4% and silver 3% by December 2026 from Wednesday's (24 December's) closing of $4,503 and $71.68 per troy ounce (1.10 gm), respectively, per Bloomberg data.
In 2025, Comex generic gold and silver futures rose 67.8% and 127%, respectively, from 1 January to 24 December, the data showed.
Indian gold and silver prices tend to mirror international prices as most domestic demand for both metals is met through imports.
Denne historien er fra December 29, 2025-utgaven av Mint Chennai.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Mint Chennai
Mint Chennai
Lenskart wants artificial intelligence to test your eyes
It expects AI-enabled eye testing to become the default foundational layer of eyecare delivery
3 mins
January 13, 2026
Mint Chennai
More companies to take a hit as labour codes debut
Reworked gratuity and leave encashments spell additional expenses for India Inc
2 mins
January 13, 2026
Mint Chennai
HC lifts ban on Zydus cancer biosimilar till patent expiry
In a relief for Zydus Lifesciences, a division bench of the Delhi High Court on Monday allowed the drugmaker to sell and market its biosimilar of the anticancer drug nivolumab in India, citing public interest.
2 mins
January 13, 2026
Mint Chennai
Trump’s investigation of Powell is also a warning to the next Fed chair
The criminal investigation into Federal Reserve Chair Jerome Powell isn’t ultimately about the Fed’s headquarters, or Powell, or even interest rates.
3 mins
January 13, 2026
Mint Chennai
States flag Almont-Kid syrup as tests find contaminants
Syrup found ‘Not of Standard Quality’ with contaminants like toxic ethylene glycol
1 mins
January 13, 2026
Mint Chennai
India at 100: Our choices today will define the next two decades
India's 2047 ambition is not guaranteed but achievable if we address all the potential pitfalls along our development path
4 mins
January 13, 2026
Mint Chennai
Now, inheritance works without probate—but why it still matters
Heirs can now act on a valid will without court cases, easing delays and unlocking assets in undisputed cases
6 mins
January 13, 2026
Mint Chennai
Why VCs have a new deep-tech playbook
where fundraising starts to drag,\" said Chand.
1 min
January 13, 2026
Mint Chennai
TCS, HCLTech deliver Q3 revenue surprise
clearer.
2 mins
January 13, 2026
Mint Chennai
US productivity is rising and it risks warping monetary policy
America's neutral rate ought to be going up but will the Fed listen?
3 mins
January 13, 2026
Listen
Translate
Change font size
